Dossier assessment
Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)
-
Dossier assessment
Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Press releases
Apremilast in plaque psoriasis and psoriatic arthritis: No added benefit can be derived
Dossiers contained neither studies of direct comparisons nor indirect comparisons
Additional information
IQWiG health information
Project details
- Project no.
- A15-09
- Commission
- Commission awarded on 16.02.2015 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair, Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Apremilast (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed